SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, Massachusetts.
Gina Chapman, President and Chief Executive Officer, is scheduled to participate in a cell therapy corporate panel discussion on Wednesday, March 6, at 9:10 a.m. EST.
A live webcast of the panel discussion will be accessible through the Investors section of CARGO’s website under News & Events. A replay of the webcast will be available after the conclusion of the live presentation for 30 days.
About CARGO
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. CARGO’s programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns and unreliable supply. CARGO is currently evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. CARGO also plans to evaluate CRG-022 in patients at earlier stages of disease, including LBCL and other hematologic malignancies. Beyond its lead program, CARGO is leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic “cargo” designed to enhance CAR T-cell persistence and trafficking to tumor lesions, as well as to help safeguard against tumor resistance and T-cell exhaustion. CARGO’s founders are pioneers and world-class experts in CAR T-cell therapy, and CARGO’s team has significant experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products.
Media Contact:
Maura Gavaghan
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Laurence Watts
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$21.99 |
| Daily Change: | -0.18 -0.81 |
| Daily Volume: | 142,172 |
| Market Cap: | US$1.010B |
August 12, 2024 July 10, 2024 May 14, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
